Synthesis of efficient gene delivery systems by grafting pegylated alkylcarboxylate chains to PAMAM dendrimers: Evaluation of transfection efficiency and cytotoxicity in cancerous and mesenchymal stem cells
Source abstract
Abstract
The applications of polyamidoamine (PAMAM) dendrimers have attracted much attention in biomedicine specially non-viral gene delivery because of thier unique characteristics including hyperbranching, multivalency, and well-defined uniform globular three-dimensional structures. In the current study, in order to enhance the transfection efficiency and reduce the cytotoxicity of PAMAMs, bromoalkylcarboxylates with different chain length (2-bromoacetic, 6-bromohexanoic, 10-bromodecanoic and 16-bromohexadecanoic acids) were covalently conjugated with 10% and 30% of primary amines of generation 4 and 5 (G4 and G5) of PAMAM dendrimers to increase the hydrophobicity of the carrier. At the next stage, the alkylcarboxylate-PAMAMs were pegylaed to further modify the PAMAM structures for biological applications. Obtained results demonstrated that the prepared PAMAM derivatives had particle size around 140 nm with net-positive surface charge. None of the prepared PAMAM-based non-viral vactors exhibited significant hemolytic activity and also cytotoxicity. Meanwhile decahexanoate–PAMAM G4 [G4(16C-10%)] and decanoate–PAMAM G4 conjugated to polyethylene glycol (PEG) (G4[(10C-30%)(10C-PEG)]) showed highest transfection efficiency in murine neuroblastoma (Neuro-2a) cell line, interestingly only the latter had improved transfection efficiency in mesenchymal stem cells (MSCs). This study proved the potential utility of alkylcarboxylate-grafted PAMAM dendrimers (G4 and G5) with or without PEG modification for efficient gene transfer into cancerous cells as well as MSCs.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Dendrimers and Hyperbranched Polymers · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Nanotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Modern Sciences and Technologies, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran
Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
References (37)
Show source-provided references
1. 10.1007/BF0325687210.1007/BF03256872 ↗
2. 10.1016/j.jconrel.2012.02.01310.1016/j.jconrel.2012.02.013 ↗
3. 10.1016/j.addr.2005.09.01810.1016/j.addr.2005.09.018 ↗
4. 10.1021/bc00023a01210.1021/bc00023a012 ↗
5. 10.1074/jbc.M30864320010.1074/jbc.M308643200 ↗
6. 10.1016/j.nano.2008.12.00710.1016/j.nano.2008.12.007 ↗
7. 10.1021/ma010634610.1021/ma0106346 ↗
8. 10.1016/j.biomaterials.2006.12.01310.1016/j.biomaterials.2006.12.013 ↗
9. 10.1021/bc060388910.1021/bc0603889 ↗
10. 10.1021/bc900228m10.1021/bc900228m ↗
11. 10.1016/j.biomaterials.2010.10.04410.1016/j.biomaterials.2010.10.044 ↗
12. 10.1021/bc900410q10.1021/bc900410q ↗
13. 10.1021/bc700483s10.1021/bc700483s ↗
14. 10.1208/s12248-009-9116-110.1208/s12248-009-9116-1 ↗
15. 10.1021/nn102100710.1021/nn1021007 ↗
16. Hashemi M · Nanomed J · 2013 · 1 · 55
17. 10.1016/j.biomaterials.2009.04.03610.1016/j.biomaterials.2009.04.036 ↗
18. 10.1002/jgm.137410.1002/jgm.1374 ↗
19. 10.1016/0003-2697(75)90431-510.1016/0003-2697(75)90431-5 ↗
20. 10.1016/j.jconrel.2008.09.00310.1016/j.jconrel.2008.09.003 ↗
21. 10.1007/s11051-014-2342-110.1007/s11051-014-2342-1 ↗
22. 10.1088/0957-4484/20/10/10510310.1088/0957-4484/20/10/105103 ↗
23. 10.7150/thno.691410.7150/thno.6914 ↗
24. 10.1021/cr800409e10.1021/cr800409e ↗
25. 10.1186/1472-6750-9-3810.1186/1472-6750-9-38 ↗
26. 10.1016/j.progpolymsci.2010.04.00710.1016/j.progpolymsci.2010.04.007 ↗
27. 10.1016/j.jconrel.2004.07.02710.1016/j.jconrel.2004.07.027 ↗
28. 10.1016/S0731-7085(00)00250-810.1016/S0731-7085(00)00250-8 ↗
29. 10.1016/S0168-3659(97)00174-010.1016/S0168-3659(97)00174-0 ↗
30. 10.1016/j.actbio.2012.07.01510.1016/j.actbio.2012.07.015 ↗
31. 10.1021/ja048548j10.1021/ja048548j ↗
32. 10.1016/j.ijpharm.2004.04.02310.1016/j.ijpharm.2004.04.023 ↗
33. 10.1089/scd.2006.15.8710.1089/scd.2006.15.87 ↗
34. 10.2174/15665231179452010210.2174/156652311794520102 ↗
35. 10.1021/bm101264710.1021/bm1012647 ↗
36. 10.1002/cbin.1005110.1002/cbin.10051 ↗
37. 10.1016/j.jconrel.2010.01.03410.1016/j.jconrel.2010.01.034 ↗